Argininosuccinic Acid
Argininosuccinic Aciduria
Argininosuccinate Lyase
Amino Acid Metabolism, Inborn Errors
Argininosuccinate Synthase
Influence of nitric oxide on vascular resistance and muscle mechanics during tetanic contractions in situ. (1/25)
Studies of the effect of nitric oxide (NO) synthesis inhibition were performed in the isometrically contracting blood-perfused canine gastrocnemius-plantaris muscle group. Muscle blood flow (Q) was controlled with a pump during continuous NO blockade produced with either 1 mM L-argininosuccinic acid (L-ArgSA) or N(G)-nitro-L-arginine methyl ester (L-NAME) during repetitive tetanic contractions (50-Hz trains, 200-ms duration, 1/s). Pump Q was set to match maximal spontaneous Q (1.3-1.4 ml. min(-1). g(-1)) measured in prior, brief (3-5 min) control contraction trials in each muscle. Active tension and oxygen uptake were 500-600 g/g and 200-230 microl. min(-1). g(-1), respectively, under these conditions. Within 3 min of L-ArgSA infusion, vascular resistance across the muscle (R(v)) increased significantly (from approximately 100 to 300 peripheral resistance units; P < 0.05), whereas R(v) increased to a lesser extent with L-NAME (from approximately 100 to 175 peripheral resistance units; P < 0.05). The increase in R(v) with L-ArgSA was unchanged by simultaneous infusion of 0.5-10 mM L-arginine but was reduced with 1-3 microg/ml sodium nitroprusside (41-54%). The increase in R(v) with L-NAME was reversed with 1 mM of L-arginine. Increased fatigue occurred with infusion of L-ArgSA; active tension and intramuscular pressure decreased by 62 and 66%, whereas passive tension and baseline intramuscular pressure increased by 80 and 30%, respectively. These data indicate a possible role for NO in the control of R(v) and contractility within the canine gastrocnemius-plantaris muscle during repetitive tetanic contractions. (+info)p(1),p(4)-diadenosine 5'-tetraphosphate induces the uptake of arginine and citrulline by a pore on the plasma membrane of bovine aortic endothelial cells. (2/25)
We have previously demonstrated that p(1),p(4)-diadenosine 5'-tetraphosphate (Ap(4)A) induces the release of nitric oxide (NO) and modulates the uptake of extracellular L-arginine (L-Arg) and L-citrulline (L-Cit) by bovine aortic endothelial cells (BAEC) [Hilderman, R.H. and Christensen, E.F. (1998) FEBS Lett. 427, 320-324 and Hilderman, R.H., Casey, T.E. and Pojoga, L.H. (2000) Arch. Biochem. Biophys. 375, 124-130]. In this communication we report that extracellular Ap(4)A enhances the uptake of L-Arg and L-Cit through a pore on the plasma membrane of BAEC that is selective for these two amino acids. We also demonstrate that Ap(2)A, which induces NO release, enhances L-Arg uptake while Ap(5)A, a vasoconstrictor, does not enhance the uptake of L-Arg. The potential physiological significance of the uptake of these two amino acids in relation to NO synthesis is discussed. (+info)On the role of substrate and GTP in the regulation of argininosuccinase activity. (3/25)
As determined by equilibrium dialysis, bovine liver argininosuccinase of molecular weight 202,000 binds 4 mol of argininosuccinate or arginine/mol of enzyme. Negative homotropic interactions occur in the binding of both ligands at 0.15 ionic strength in the presence of phosphate. Argininosuccinate binds to two sites (Kdiss 1.6 times 10(-5) M) and four sites (Kdiss 2.9 times 10(-4) M) at low and high substrate concentration. Similarly, arginine binds to two sites (Kdiss 4.9 times 10(-4) M), and four sites (Kdiss 1.6 times 10(-3) M). At 0.05 ionic strength in Tris-HCl buffer, the four enzyme sites bind argininosuccinate independently and arginine binding remains negatively cooperative. Kinetic analysis gave double reciprocal plots that showed negative cooperatively also. The changes in Km were analogous to changes in Kdiss, thus indicating that the substrate binding sites correspond to catalytic sites. Since the catalytically active enzyme is a tetramer composed of four identical or closely similar subunits (Lusty, C.J., and Ratner, S. (1972) J. Biol. Chem. 247, 7010-7022), the present results show that each subunit contains one catalytic site. Ionic strength, phosphate ions, and GTP have each been found to influence negative cooperatively through a change in the affinity for argininosuccinate. The significance of the negative homotropic interactions and of the specific stimulation of activity by GTP is discussed with respect to different conformational forms of the enzyme and the in vivo regulation of argininosuccinase activity. (+info)A novel stop codon mutation (X465Y) in the argininosuccinate lyase gene in a patient with argininosuccinic aciduria. (4/25)
Argininosuccinate lyase (ASL) deficiency (McKusick 207900) is a rare autosomal recessive disorder affecting the urea cycle. The cardinal symptom in the neonatal form is progressive hyperammonemia, which is often life-threatening. However, clinical symptoms in the late onset form are quite heterogeneous. As well as measurement of ASL activity, analysis of the ASL gene is necessary to clarify the genetic basis of various phenotypes. We report a patient with late onset argininosuccinate lyase deficiency (ASLD) who had hepatomegaly and mildly increased level of ammonia. By mutation analysis of the mRNA and genomic DNA from the patient's leukocytes, we identified a novel missense mutation 1395G>C in the homozygous state, which results in the exchange of a stop codon to tyrosine at amino acid position 465 (X465Y). This unique mutation causes an elongation of fifty amino acids in the C-terminal region of the ASL protein, and is likely related to a milder phenotype compared with previously reported mutations. In addition, this is the first report on mutation analysis in a Japanese ASLD patient. (+info)Unknown syndrome in sibs: pili torti, growth delay, developmental delay, and mild neurological abnormalities. (5/25)
We present male and female sibs of consanguineous parents with features including pili torti with unusual hair shaft electron microscopic (EM) findings, growth delay, developmental delay, and mild to moderate neurological abnormalities. The features of the cases presented here have not been noted in the previously reported clinical syndromes in which pili torti may be found. (+info)Induction of nitric oxide synthase-2 proceeds with the concomitant downregulation of the endogenous caveolin levels. (6/25)
Several cell types express inducible nitric oxide synthase (NOS2) in response to exogenous insults such as bacterial lipopolysaccharide (LPS) or proinflammatory cytokines. For instance, muscular cells treated with LPS and interferon gamma (IFN-gamma) respond by increasing the mRNA and protein levels of NOS2, and synthesize large amounts of nitric oxide. We show here that transcriptional induction of NOS2 in muscular cells proceeds with a concomitant decrease in the levels of caveolin-1, -2 and -3. Addition of *NO-releasing compounds to C2C12 muscle cells reveals that this downregulation of the caveolin (cav) levels is due to the presence of *NO itself in the case of caveolin-3 and to the action of the LPS/IFN-gamma in the case of cav-1 and cav-2. Likewise, muscle cells obtained from NOS2(-/-) knockout mice challenged with LPS/IFN-gamma could downregulate their levels of cav-1 but not of cav-3, unlike wild-type animals, in which both cav-1 and cav-3 levels diminished in the presence of the proinflammatory insult. Laser confocal immunofluorescence analysis proves that *NO exerts autocrine and paracrine actions, hence diminishing the cav-3 levels. When the induced NOS2 was purified using an affinity resin or immunoprecipitated from muscular tissues, it appears strongly bound not only to calmodulin but also to cav-1, and marginally to cav-2 and cav-3. When the cav levels where reduced using antisense oligonucleotides, an increase in the NOS2-derived.NO levels could be measured, demonstrating the inhibitory role of the three cav isoforms. Our results show that cells expressing NOS2 diminish their cav levels when the synthesis of *NO is required. (+info)Structural studies of duck delta2 crystallin mutants provide insight into the role of Thr161 and the 280s loop in catalysis. (7/25)
Delta crystallin, a taxon-specific crystallin present in avian eye lenses, is homologous to the urea cycle enzyme ASL (argininosuccinate lyase). Although there are two delta crystallin isoforms in duck lenses, ddeltac1 (duck delta1 crystallin) and ddeltac2 (duck delta2 crystallin), only ddeltac2 is catalytically active. Previous structural studies have suggested that residues Ser283 and His162 in the multi-subunit active site of ddeltac2/ASL are the putative catalytic acid/base, while the highly conserved, positively charged Lys289 is thought to help stabilize the carbanion intermediate. The strict conservation of a small hydroxy-containing residue (Thr or Ser) at position 161 adjacent to the putative catalytic base, as well as its proximity to the substrate in the S283A ddeltac2 enzyme-substrate complex, prompted us to investigate further the role this residue. Structures of the active T161S and inactive T161D ddeltac2 mutants, as well as T161D complexed with argininosuccinate, have been determined to 2.0 A resolution. The structures suggest that a hydroxy group is required at position 161 to help correctly position the side chain of Lys289 and the fumarate moiety of the substrate. Threonine is probably favoured over serine, because the interaction of its methyl group with Leu206 would restrict its conformational flexibility. Residues larger than Thr or Ser interfere with substrate binding, supporting previous suggestions that correct positioning of the substrate's fumarate moiety is essential for catalysis to occur. The presence of the 280s loop (i.e. a loop formed by residues 270-290) in the 'open' conformation suggests that loop closure, thought to be essential for sequestration of the substrate, may be triggered by the formation of the carbanion or aci-carboxylate intermediates, whose charge distribution more closely mimics that of the sulphate ion found in the active-site region of the inactive ddeltac1. The 280s loop in ddeltac1 is in the closed conformation. (+info)Neonatal argininosuccinic aciduria with normal brain and kidney but absent liver argininosuccinate lyase activity. (8/25)
An infant is described who died at 6 days of age with hyperammonemia and argininosuccinic acid in the urine. Argininosuccinic acid lyase (AL) was absent in liver, decreased in red blood cells, but normal in brain and kidney. The instability of AL in frozen stored tissues accounts for previous reports of deficient AL activity in the brain and kidney of neonates with this disease. The variation of AL activity in the tissues of this patient demonstrates that more than one gene locus either codes for the structure of this enzyme or regulates its biosynthesis in different organs. (+info)Symptoms of argininosuccinic aciduria typically appear during infancy or early childhood and may include seizures, developmental delays, intellectual disability, vision loss, and poor muscle tone. Treatment for this condition involves a strict diet that limits the intake of certain amino acids, as well as medication to manage seizures and other symptoms. In some cases, liver transplantation may be necessary.
Argininosuccinic aciduria is diagnosed through a combination of clinical evaluation, laboratory tests, and genetic analysis. Treatment is usually coordinated by a multidisciplinary team of healthcare professionals, including pediatricians, neurologists, metabolism specialists, dietitians, and psychologists. With appropriate treatment and management, many individuals with argininosuccinic aciduria are able to lead active and fulfilling lives.
Overall, argininosuccinic aciduria is a rare and complex genetic disorder that requires careful management and monitoring to prevent complications and improve quality of life for affected individuals.
There are several types of inborn errors of amino acid metabolism, including:
1. Phenylketonuria (PKU): This is the most common inborn error of amino acid metabolism and is caused by a deficiency of the enzyme phenylalanine hydroxylase. This enzyme is needed to break down the amino acid phenylalanine, which is found in many protein-containing foods. If phenylalanine is not properly broken down, it can build up in the blood and brain and cause serious health problems.
2. Maple syrup urine disease (MSUD): This is a rare genetic disorder that affects the breakdown of the amino acids leucine, isoleucine, and valine. These amino acids are important for growth and development, but if they are not properly broken down, they can build up in the blood and cause serious health problems.
3. Homocystinuria: This is a rare genetic disorder that affects the breakdown of the amino acid methionine. Methionine is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
4. Arginase deficiency: This is a rare genetic disorder that affects the breakdown of the amino acid arginine. Arginine is important for the body's production of nitric oxide, a compound that helps to relax blood vessels and improve blood flow.
5. Citrullinemia: This is a rare genetic disorder that affects the breakdown of the amino acid citrulline. Citrulline is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
6. Tyrosinemia: This is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Tyrosine is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
7. Maple syrup urine disease (MSUD): This is a rare genetic disorder that affects the breakdown of the amino acids leucine, isoleucine, and valine. These amino acids are important for growth and development, but if they are not properly broken down, they can build up in the blood and cause serious health problems.
8. PKU (phenylketonuria): This is a rare genetic disorder that affects the breakdown of the amino acid phenylalanine. Phenylalanine is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
9. Methionine adenosyltransferase (MAT) deficiency: This is a rare genetic disorder that affects the breakdown of the amino acid methionine. Methionine is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
10. Homocystinuria: This is a rare genetic disorder that affects the breakdown of the amino acid homocysteine. Homocysteine is important for the body's production of proteins and other compounds, but if it is not properly broken down, it can build up in the blood and cause serious health problems.
It is important to note that these disorders are rare and affect a small percentage of the population. However, they can be serious and potentially life-threatening, so it is important to be aware of them and seek medical attention if symptoms persist or worsen over time.
Argininosuccinic acid
Argininosuccinate synthase
Argininosuccinate synthetase 1
Citrullinemia
Argininosuccinic aciduria
Canaline
Coral Barbas
Sarah Ratner
List of MeSH codes (D02)
Urea cycle
Citrullinemia type I
Sodium phenylbutyrate
Charles Enrique Dent
List of disorders included in newborn screening programs
List of lay Catholic scientists
List of OMIM disorder codes
List of diseases (A)
Newborn screening
ASA
List of MeSH codes (D12.125)
Argininosuccinate lyase
Argininosuccinic aciduria - Living with the Disease - Genetic and Rare Diseases Information Center
DailyMed - BUPHENYL- sodium phenylbutyrate tablet
BUPHENYL- sodium phenylbutyrate powder
Argininosuccinate lyase deficiency - PubMed
New Tool Improves Newborn Screening Accuracy
Citrullinemia Workup: Laboratory Studies, Imaging Studies, Other Tests
ASS1 gene: MedlinePlus Genetics
MeSH Browser
Newborn Screening Codes
DeCS
MeSH Browser
MESH TREE NUMBER CHANGES - 2013 MeSH. August 27, 2012
Argininosuccinic aciduria: MedlinePlus Genetics
Amino acids basic. Medical search
Pesquisa | Biblioteca Virtual em Saúde - BRASIL
Carglumic Acid - LiverTox - NCBI Bookshelf
Newborn screening tests for your baby | March of Dimes
DailyMed - BUPHENYL- sodium phenylbutyrate tablet
BUPHENYL- sodium phenylbutyrate powder
NDF-RT Code NDF-RT Name
MESH TREE NUMBER CHANGES - 2002 MeSH
CLASSIFICATION OF DISEASES AND INJURIES
Urea Cycle Disorders Market Size & Share, Trends, Epidemiology and Competitive Insights Report 2032 | Companies - Acer...
Amino Acid Analysis - INSTAND e.V.
Pipeline
MESH TREE NUMBER CHANGES - 2013 MeSH. August 27, 2012
Medicine:Newborn screening - HandWiki
WHO EMRO | Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011 |...
Citrulline3
- This step combines two protein building blocks (amino acids), citrulline and aspartate, to form a molecule called argininosuccinic acid. (medlineplus.gov)
- This amino acid is formed during the urea cycle from citrulline, aspartate and ATP. (bvsalud.org)
- Nine metabolites, including L-acetylcarnitine, and citrulline were elevated in the urine, and trimethylamine N-oxide, adrenic acid, and 10 other metabolites were reduced. (bvsalud.org)
Aciduria1
- each is referred to by the initials of the missing enzyme: CPS1 (Carbamoyl Phosphate Synthetase), NAGS (N-Acetylglutamate Synthetase), OTC Deficiency (Ornithine Transcarbamylase), AS (Argininosuccinic Acid Synthetase (Citrullinemia)), ASL (Argininosuccinate Lyase (Argininosuccinic Aciduria)), and AG (Arginase). (rohtaknewsmagazine.net)
Citrullinemia1
- Most of the mutations involved in type I citrullinemia change single amino acids in the argininosuccinate synthase 1 enzyme. (medlineplus.gov)
Synthetase1
- This reaction is catalyzed by argininosuccinic acid synthetase. (bvsalud.org)
Fatty3
- ABSTRACT The national neonatal screening programme in the United Arab Emirates currently includes 16 disorders: congenital hypothyroidism, sickle-cell diseases, congenital adrenal hyperplasia, biotinidase deficiency and 12 amino acid, organic acid and fatty acid disorders. (who.int)
- The incidence of screened disorders were 1:1 873 for congenital hypothyroidism, 1:14 544 for phenylketonuria, 1:3 526 for amino acid, organic acid and fatty acid disorders, 1:9 030 for classical congenital adrenal hyperplasia, 1:8 300 for biotinidase deficiency, 1:2 384 for sickle-cell disease and 1:121 for sickle-cell traits. (who.int)
- Because short-chain acyl-CoA dehydrogenase deficiency (SCADD) (the result of an intramitochondrial defect in the beta-oxidation of fatty acids) may impair this form of energy production, metabolic crisis may result. (medicalhomeportal.org)
Deficiency1
- Patients with PKU require supplementation of amino acids formulated as foods for special medical purposes ("FSMP") to prevent protein deficiency. (relieftherapeutics.com)
Urea1
- A series of additional chemical reactions uses argininosuccinic acid to form urea. (medlineplus.gov)
Disorders1
- Traditionally the inherited metabolic diseases were categorized as disorders of carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage diseases . (chemeurope.com)
Amino Acid Analysis1
- Routine plasma amino acid analysis measures free plasma homocystine, not total plasma homocystine. (medilib.ir)
Urine1
- Follow-up testing usually involves a quantitative plasma acylcarnitine profile, urine organic acids (increased ethylmalonic acid), and urine acylglycine analysis. (medicalhomeportal.org)
Phenylketonuria1
- NBS started with the discovery that the amino acid disorder phenylketonuria (PKU) could be treated by dietary adjustment, and that early intervention was required for the best outcome. (handwiki.org)
Phenylalanine1
- Infants with PKU appear normal at birth, but are unable to metabolize the essential amino acid phenylalanine , resulting in irreversible intellectual disability . (handwiki.org)
Patterns1
- [3] The development of tandem mass spectrometry (MS/MS) screening in the early 1990s led to a large expansion of potentially detectable congenital metabolic diseases that can be identified by characteristic patterns of amino acids and acylcarnitines . (handwiki.org)
Analysis1
- Further analysis was conducted on the relationship between Lactobacillus and Akkermansia bacteria with metabolites, and it was found that they are mainly related to amino acid metabolites. (bvsalud.org)
Profile1
- PKU GOLIKE ® , engineered with the patent protected, proprietary drug delivery technology named "Physiomimic," is the first prolonged-release amino acid mix product that (i) mimics the absorption profile of dietary proteins while (ii) offering effective taste and odor masking. (relieftherapeutics.com)
Aciduria12
- For example, several amino acid disorders, including argininosuccinic aciduria, citrullinemia and Ornithine transcarbamylase deficiency, are represented by the code 270.6. (nih.gov)
- Argininosuccinic aciduria is an inherited disorder that causes ammonia to accumulate in the blood. (nih.gov)
- Argininosuccinic aciduria usually becomes evident in the first few days of life. (nih.gov)
- An infant with argininosuccinic aciduria may be lacking in energy (lethargic) or unwilling to eat, and have a poorly controlled breathing rate or body temperature. (nih.gov)
- Complications from argininosuccinic aciduria may include developmental delay and intellectual disability. (nih.gov)
- Argininosuccinic aciduria occurs in approximately 1 in 70,000 to 218,000 newborns. (nih.gov)
- Mutations in the ASL gene cause argininosuccinic aciduria. (nih.gov)
- In people with argininosuccinic aciduria, argininosuccinate lyase is dysfunctional or missing. (nih.gov)
- This buildup of ammonia damages the brain and other tissues and causes neurological problems and other signs and symptoms of argininosuccinic aciduria. (nih.gov)
- Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. (nih.gov)
- This occurs in patients with argininosuccinic aciduria, despite the fact that formation of this substance ensures incorporation of the 2 waste nitrogen molecules normally found in urea. (medscape.com)
- Inherited as an autosomal recessive trait, argininosuccinic aciduria affects both sexes equally. (medscape.com)
Lyase5
- To date, two variants of argininosuccinic acid lyase deficiency, the second most common enzymatic defect of the urea cycle, have been described. (nih.gov)
- Since 1973, 12 Austrian children suffering from argininosuccinic acid lyase deficiency have been detected in the Austrian Neonates Screening Program and could have been followed up. (nih.gov)
- It can be concluded that early treatment of partial argininosuccinic acid lyase deficiency results in normal intellectual and psychomotor development. (nih.gov)
- The specific role of the argininosuccinate lyase enzyme is to start the reaction in which the amino acid arginine, a building block of proteins, is produced from argininosuccinate, the molecule that carries the waste nitrogen collected earlier in the urea cycle. (nih.gov)
- Compound 5 is fumaric acid generated in the reaction that converts ASA to arginine (6), which is mediated by ASA lyase. (medscape.com)
Citrullinemia1
- Most of the mutations involved in type I citrullinemia change single amino acids in the argininosuccinate synthase 1 enzyme. (medlineplus.gov)
Essential amino2
- Monitoring the concentration of plasma amino acids to identify deficiency of essential amino acids and impending hyperammonemia at intervals depending on age and metabolic status. (nih.gov)
- The formation of propionyl CoA in human metabolism is derived from many sources, chiefly catabolism of a number of essential amino acids (isoleucine, valine, threonine, methionine). (medscape.com)
Urea cycle1
- Overall, the hepatic urea cycle is the major route for waste nitrogen disposal, generation of which is chiefly from protein and amino acid metabolism. (medscape.com)
Synthase1
- Studies suggest that the underlying cause of the hyperammonemia is the inhibition of N -acetylglutamate synthase (NAGS) activity by free propionic acid. (medscape.com)
Hyperammonemia1
- [ 44 ] Other categories of EM that also present after 24 hours of age with hyperammonemia include organic acidemias and fatty acid oxidation disorders. (medscape.com)
Chiefly1
- nitrogen generation results chiefly from protein and amino acid metabolism. (medscape.com)
Genetic1
- en 8 EN ONIN Besides the specific research projects to be funded under the Center grant, we work in an extensive context of genetic and related research -- and indispensable aspect of our own environment, and a set of activities to which the Center organiza- tion may also bring a new focus for developments that should advance both basic scientific knowledge and its application to human problems. (nih.gov)
Molecular1
- It is known chemically as 4-phenylbutyric acid, sodium salt with a molecular weight of 186 and the molecular formula C 10 H 11 O 2 Na. (nih.gov)